Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jac/dkaa441 http://scihub22266oqcxt.onion/10.1093/jac/dkaa441 33221868!7717306!33221868     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Antimicrob+Chemother 2021 ; 76 (2): 482-486 Nephropedia Template TP {{tp|p=33221868|t=2021. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection |pdf=|usr=}}{{33221868}} gab.com Text Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection JO: J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33221868 #FOAvip BACKGROUND: Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection. OBJECTIVES: To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. METHODS: This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines. RESULTS: Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration. CONCLUSIONS: Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease. Twit Text FOAVip Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection ????J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33221868 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33221868 #FOAvip English Wikipedia <ref>{{Cite pmid|33221868}}</ref> Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection #MMPMID33221868 Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F J Antimicrob Chemother 2021[Jan]; 76 (2): 482-486 PMID33221868show ga BACKGROUND: Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection. OBJECTIVES: To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. METHODS: This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines. RESULTS: Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration. CONCLUSIONS: Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/administration & dosage/*adverse effects/blood/therapeutic use[MESH] |COVID-19/epidemiology[MESH] |Cohort Studies[MESH] |Darunavir/administration & dosage/*adverse effects/blood/therapeutic use[MESH] |Drug Therapy, Combination[MESH] |Electrocardiography[MESH] |France[MESH] |Humans[MESH] |Hydroxychloroquine/administration & dosage/*adverse effects/blood/therapeutic use[MESH] |Long QT Syndrome/chemically induced/epidemiology[MESH] |Lopinavir/administration & dosage/*adverse effects/blood/therapeutic use[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 in(epmc).pdf DeepDyve Pubget Overpricing